The last few weeks may feel like months for investors trying to make sense of huge swings to the upside and the downside in the broader market. The Nasdaq Composite's (^IXIC 0.64%) over 12% pop on April 9 pole-vaulted the index out of bear market territory -- which is a decline of over 20% from a recent high. However, a subsequent sell-off on Thursday pushed the Nasdaq within striking distance of being back in a bear market.Bear markets have historically been phenomenal times to put hard-earned savings to w ...

Group 1: Dividend Reliability - ExxonMobil has raised its dividend for 42 consecutive years, demonstrating resilience despite economic downturns in the oil and gas industry [3][4] - The company maintained its dividend during the 2020 economic collapse, relying on a strong balance sheet [4] Group 2: Financial Health - ExxonMobil's net total long-term debt is $14.7 billion, with a debt-to-equity ratio of 0.08 and a debt-to-capital ratio of 12.5%, indicating reduced dependence on debt [5][6] - The company has the lowest debt-to-capital ratio among major integrated U.S. and European oil and gas companies [6] Group 3: Cost Structure and Future Outlook - ExxonMobil has improved its cost structure and technological advancements, allowing it to support dividends even if oil and gas prices decline [7] - The company has a long-term plan through 2030, expecting a cash surplus of $110 billion even at a pessimistic Brent crude price of $55 per barrel [8][9] Group 4: Competitive Advantages - ExxonMobil's diversified oil and gas production portfolio and significant refining business position it well to navigate market slowdowns [11] - The company is not reliant on a single geographic region, allowing it to capture market share during downturns [11][12] Group 5: Dividend Yield - ExxonMobil offers a dividend yield of 4%, providing a reliable source of passive income for investors [14]

The Nasdaq-100 index is home to 100 of the largest non-financial companies listed on the Nasdaq stock exchange, including each of the "Magnificent Seven" stocks, which have a combined value of $14.7 trillion:Apple: $3 trillion.Microsoft: $2.9 trillion.Nvidia (NVDA -0.18%): $2.7 trillion.Amazon: $2 trillion.Alphabet (GOOG 1.21%) (GOOGL 1.12%): $1.9 trillion.Meta Platforms: $1.4 trillion.Tesla: $811 billion.Their size is just one of the reasons Wall Street named these stocks the Magnificent Seven in 2023. Eac ...

FX Empire Logo Português Deutsch العربية Français Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ow ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

Core Viewpoint - The recent volatility in Wall Street, driven by tariff and trade uncertainties, has created opportunities for investors to capitalize on industry leaders during a bear market, particularly with a small investment amount like $300 [1][3][4]. Market Overview - The Dow Jones Industrial Average, S&P 500, and Nasdaq Composite experienced significant fluctuations, with the Nasdaq entering a bear market, sitting 18.8% below its all-time high as of April 10 [2][3]. - The Nasdaq's volatility included its largest single-session point gain followed by one of its largest declines, indicating extreme market conditions [2]. Investment Opportunities Alphabet (GOOGL) - Alphabet, the parent company of Google, YouTube, and Google Cloud, is highlighted as a strong investment despite concerns over a potential recession impacting advertising revenue, which constitutes 75% of its sales [6][7]. - Historically, U.S. recessions have been short-lived, and Alphabet's dominant market position in internet search (89% to 93% share) supports its advertising pricing power [8][9]. - The growth of Google Cloud and its cash-rich balance sheet ($95.7 billion) position Alphabet well for future investments and stock buybacks, making it an attractive buy at a forward earnings multiple of 15 times [10][11][12]. AstraZeneca (AZN) - AstraZeneca is presented as a resilient investment in the pharmaceutical sector, which remains stable during market volatility due to consistent demand for medications [13][14]. - The company has shown strong sales growth across its core areas, particularly in oncology (24% growth) and cardiovascular (20% growth) sectors [15]. - AstraZeneca's acquisition of Alexion Pharmaceuticals enhances its portfolio in rare diseases, providing pricing power and long-term cash flow stability, with the stock trading at less than 11 times forecast EPS [16][17]. The Trade Desk (TTD) - The Trade Desk, an adtech company, is noted for its potential despite the challenges posed by market volatility and recession fears affecting advertising budgets [18][19]. - The company is positioned to benefit from the shift towards digital advertising, with expected revenue growth of around 20% annually and a historically low valuation at 22 times forward-year EPS [21][23]. - The adoption of Unified ID 2.0 technology by digital companies enhances The Trade Desk's role in the evolving advertising landscape, particularly in connected TV platforms [22].

Although the market rebounded sharply on Wednesday on news that President Trump was pausing tariffs and only levying a flat 10% rate, except for China, the Nasdaq is still in a bear market. Bear markets start when an index drops 20% from its all-time high and technically remain in bear market status until a new all-time high is reached, which then kicks off a bull market.Regardless of the technical definition of a bear market, there are still plenty of bargains to be scooped up right now, and I think invest ...

Core Viewpoint - The Nasdaq Composite index has experienced significant volatility, recently entering a bear market but showing signs of recovery, presenting potential buying opportunities for long-term investors in select stocks [2][3]. Group 1: Alphabet - Alphabet's share price is down approximately 25% from its all-time high earlier this year, creating a favorable buying opportunity for long-term investors [4]. - The company has a price-to-earnings-to-growth (PEG) ratio of 1.04, indicating reasonable valuation based on five-year earnings growth projections [4]. - Google Cloud is the fastest-growing major cloud services provider, and the rollout of its Gemini large language model has positioned it competitively against OpenAI's ChatGPT [5]. - Google Search has integrated generative AI features, leading to increased search usage and user satisfaction, which is expected to drive robust growth [6]. - Future revenue growth is anticipated from Alphabet's Waymo self-driving car technology unit [6]. Group 2: Intuitive Surgical - Intuitive Surgical's share price is down about 6% from the beginning of the year, but it remains a strong long-term investment [7]. - The company has over 10,670 robotic surgical systems installed globally, with nearly 2.7 million procedures performed last year, showcasing its market leadership [8]. - A significant 84% of Intuitive Surgical's total revenue in 2024 is expected to come from recurring sources, up from 71% in 2017, indicating strong cash flow [9]. - The company estimates that there are 8 million procedures annually that it can target, which is nearly three times its current procedure volume, with additional potential in 22 million procedures under development [10]. Group 3: Vertex Pharmaceuticals - Vertex Pharmaceuticals has achieved a 17.5% gain so far in 2025, indicating strong momentum [12]. - The company holds a virtual monopoly in treating cystic fibrosis, bolstered by the FDA approval of Alyftrek, which offers more convenient dosing and potentially higher profitability [13]. - Vertex's new drug Journavx, approved in January, is the first new class of pain medication in over 20 years, expected to be commercially successful due to its non-addictive properties [14]. - The company is also advancing the rollout of Casgevy, a gene-editing therapy for sickle cell disease, and has a promising pipeline with four late-stage programs, including one aimed at curing severe type 1 diabetes [15].

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading activities [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to understand how these instruments work and the associated risks before investing [1].

With the Nasdaq Composite in bear market territory, many stocks look like absolute bargains compared to their previous values. One of those stocks is Nvidia (NVDA 1.94%), which has been practically the No. 1 stock to own in the market since 2023.With the stock down around 35% from its all-time high, many investors are likely wondering if buying Nvidia today could be the deal of a lifetime and give them fantastic returns and help set them up for life. Is this true? Or is Nvidia a value trap here?The AI race ...